Analyse Perspective Therapeutics, Inc. (CATX) — Kairos Score 59/100

À propos de Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.

Informations clés

🕴️ Activité des initiés (90 jours)

5 transactions — 0 achats et 5 ventes déclarés par les dirigeants de Perspective Therapeutics, Inc..

🏦 Hedge Funds

16 fonds institutionnels déclarent une position sur CATX dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur CATX.

• Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors
• Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.